A review of recent data regarding maintenance therapy for patients with AML who achieve first remission, including updates from the 2023 ASH Annual meeting.
Insight into monitoring patients who are being treated for AML, what constitutes complete remission, and how and why it’s important to test for minimal residual disease to determine a patient’s risk for relapse.
Revumenib sheds light on AML patients as the drug potentially treats their cancer. A group of researchers conducted phase one of clinical trials between 2019 to 2022 for an anti-cancer drug on patients living with acute myeloid leukemia (AML).